Boston, MA 09/19/2014 (wallstreetpr) – Biopharmaceutical company, Opexa Therapeutics Inc (NASDAQ:OPXA) Director, Barabe Timothy, has followed its colleague in the board and the company’s President and Chief Executive Officer, Neil Warma, in buying the company’s shares. They were the two persons to acquire the shares in the current month.
Buys Shares
Opexa Therapeutics Inc (NASDAQ:OPXA)’s Director, Timothy, was the most recent person to acquire 10,000 shares on September 17 at the rate of $1.15 a share, according to a Form 4 filed with the Securities and Exchange Commission on September 18. This has tightened his purse by $11,500. It meant that he has paid seven cents a share more than the company’s lowest price of $1.08 in the last 52-week period. Alternatively, the Director has paid 6.5% premium.
However, based on the one-year high price of $2.56, the purchase price represented a discount of 55.1%. The latest purchase has improved the Director’s holding to 16,000 shares in the company, which was worth $17,920.
Only the previous day, i.e. on September 16, Opexa Therapeutics CEO has purchased 10,000 shares at the rate of $1.11 a share, as per the data from Nasdaq. This has lifted his direct holding in the company to 107,634 shares valued approximately $120550.
One-Year Insider Trading
There were only two buying activities in the last three-month period, and that has happened only in September. Before this, Timothy has purchased 6,000 shares from non-open market on March 19. Therefore, only 20,000 shares were acquired by the insiders during the three-month period.
Similarly, for the 52-week period, there were fourteen transactions of insider trading activities, and everything was related to purchasing of 538,995 shares. The fact that there were no sellers in the last one-year period indicates the confidence that the insiders have in Opexa Therapeutics Inc (NASDAQ:OPXA) product pipeline. It could well mean that those who buy the shares now can reap a rich harvest when Opexa Therapeutics Inc (NASDAQ:OPXA) announces any favorable news on the products pipeline.
Interestingly, Opexa Therapeutics Inc (NASDAQ:OPXA) has recently announced that it has commenced development of a second indication, Neuromyelitis optica or NMO, which is a unusual
